Recent advances in pharmacological treatment of irritable bowel syndrome

Table 2 Pharmacological treatment irritable bowel syndrome-C studies and clinical efficacy during last 5 years

Category/No. of studies/Ref.	n	vs Placebo	Abdominal distention/pain	QOL/patient satisfaction/global improvement	Stool consistency/bowel habits	Recommendation vs placebo
5-HT3 antagonists
Alosetron, cilansetron/4
Cremonini et al[79] 2012	705	Yes	-	SS	-	Superior
Rahimi et al[80] 2008	4.17	Yes	SS	SS	-	Superior
	Metanalysis
Andresen et al[81] 2008	7487 Metanalysis	Yes or mebeverine	SS	SS	-	Superior
Ford et al[82] 2009	7216	Yes	SS	SS	-	Superior
	Metanalysis
Ramosetron/3
Matsueda et al[85] 2008	418	Yes	SS (5/10 μg)	SS (5/10 μg)	-	Superior
Matsueda et al[86] 2008	539	Yes	SS (5 μg)	SS (5 μg)	SS (5 μg)	Superior
Lee et al[87] 2011	343	Mebeverine	NS(5 μg)	NS (5 μg)	NS(5 μg)	Equal
		135 mg t.i.d
LX-1031/1
Brown et al[92] 2011	155	Yes	SS only the 1st week (1000 mg 4 times/d)	-	SS (1000 mg 4 times/d)	Superior
Crofelemer/1
Angel et al[94] 2008	246	Yes	SS 500 mg b.i.d	SS	SS	Superior
Antibiotics
Rifaximin/2
Pimentel et al[105] 2011	1260	Yes	SS	SS	SS	Superior
Menees et al[106] 2012	1803	Yes	SS	SS	-	Superior
	Metanalysis
5ASA compounds, mesalazine/3
Corinaldesi et al[108] 2009	20	Yes	NS	SS	NS	Equal
Andrews et al[109] 2011	12	No	SS	SS	-	-
		Comparison to baseline
Tuteja et al[110] 2012	17	Yes	NS	NS	NS	Equal

QOL: Quality of life; ASA: Aminosalicylic acid; SS: Statistically significant; NS: Not significant.